Roche Purchase of Igen Resolves Licensing Dispute, Preserves Technology
This article was originally published in The Gray Sheet
Executive Summary
Roche Diagnostics will retain roughly $400 mil. in annual revenues through the $1.4 bil. acquisition of Origen electrochemilumunescence technology licensor Igen International